河北医药
河北醫藥
하북의약
Hebei Medical Journal
2015年
19期
2885-2888
,共4页
朱鑫%王亚轩%常学良%韩振伟%滕志海%王志胜%高栩%郭绍卫%李景东%黎玮
硃鑫%王亞軒%常學良%韓振偉%滕誌海%王誌勝%高栩%郭紹衛%李景東%黎瑋
주흠%왕아헌%상학량%한진위%등지해%왕지성%고허%곽소위%리경동%려위
HDAC1%E2F1%肾透明细胞癌%RT-PCR%免疫组化
HDAC1%E2F1%腎透明細胞癌%RT-PCR%免疫組化
HDAC1%E2F1%신투명세포암%RT-PCR%면역조화
HDAC1%E2F1%ccRCC%RT-PCR%immunohistochemistry
目的:探讨组蛋白去乙酰化酶1( HDAC1)、转录因子E2 F1在人肾透明细胞癌中的表达和意义。方法应用免疫组织化学法检测51例肾透明细胞癌组织、24例癌旁正常组织中HDAC1、E2F1的蛋白表达情况。 RT-PCR方法检测31例肾透明细胞癌组织、14例癌旁正常组织中HDAC1、 E2F1的mRNA相对表达情况。观察HDAC1及E2F1的表达与临床病理特征的关系。结果免疫组化结果显示:HDAC1蛋白在肾透明细胞癌组织中的阳性表达率,高于癌旁正常组织( P <0湝.05);E2F1蛋白在肾透明细胞癌组织中的阳性表达率,高于癌旁正常组织( P <0.05);HDAC1与E2F1的蛋白表达与患者性别、年龄及瘤体大小无关( P >0.05),而与组织学分级及临床分期有关( P <0.05)。 RT-PCR结果显示:HDAC1mRNA在肾透明细胞癌组织中的相对表达量,高于癌旁正常组织( P <0.05);E2 F1mRNA在肾透明细胞癌组织中的相对表达量,高于癌旁正常组织( P <00.5);HDAC1与E2F1的mRNA相对表达量与患者性别、年龄及瘤体大小无关( P >0.05),而与组织学分级及临床分期有关( P <0.05)。结论 HDAC1与E2 F1在肾透明细胞癌中的表达高于癌旁正常组织,且与组织学分级及临床分期有关,并随组织恶性程度的增加其表达水平逐渐增加,提示与肾透明细胞癌的进展有密切关系。
目的:探討組蛋白去乙酰化酶1( HDAC1)、轉錄因子E2 F1在人腎透明細胞癌中的錶達和意義。方法應用免疫組織化學法檢測51例腎透明細胞癌組織、24例癌徬正常組織中HDAC1、E2F1的蛋白錶達情況。 RT-PCR方法檢測31例腎透明細胞癌組織、14例癌徬正常組織中HDAC1、 E2F1的mRNA相對錶達情況。觀察HDAC1及E2F1的錶達與臨床病理特徵的關繫。結果免疫組化結果顯示:HDAC1蛋白在腎透明細胞癌組織中的暘性錶達率,高于癌徬正常組織( P <0湝.05);E2F1蛋白在腎透明細胞癌組織中的暘性錶達率,高于癌徬正常組織( P <0.05);HDAC1與E2F1的蛋白錶達與患者性彆、年齡及瘤體大小無關( P >0.05),而與組織學分級及臨床分期有關( P <0.05)。 RT-PCR結果顯示:HDAC1mRNA在腎透明細胞癌組織中的相對錶達量,高于癌徬正常組織( P <0.05);E2 F1mRNA在腎透明細胞癌組織中的相對錶達量,高于癌徬正常組織( P <00.5);HDAC1與E2F1的mRNA相對錶達量與患者性彆、年齡及瘤體大小無關( P >0.05),而與組織學分級及臨床分期有關( P <0.05)。結論 HDAC1與E2 F1在腎透明細胞癌中的錶達高于癌徬正常組織,且與組織學分級及臨床分期有關,併隨組織噁性程度的增加其錶達水平逐漸增加,提示與腎透明細胞癌的進展有密切關繫。
목적:탐토조단백거을선화매1( HDAC1)、전록인자E2 F1재인신투명세포암중적표체화의의。방법응용면역조직화학법검측51례신투명세포암조직、24례암방정상조직중HDAC1、E2F1적단백표체정황。 RT-PCR방법검측31례신투명세포암조직、14례암방정상조직중HDAC1、 E2F1적mRNA상대표체정황。관찰HDAC1급E2F1적표체여림상병리특정적관계。결과면역조화결과현시:HDAC1단백재신투명세포암조직중적양성표체솔,고우암방정상조직( P <0개.05);E2F1단백재신투명세포암조직중적양성표체솔,고우암방정상조직( P <0.05);HDAC1여E2F1적단백표체여환자성별、년령급류체대소무관( P >0.05),이여조직학분급급림상분기유관( P <0.05)。 RT-PCR결과현시:HDAC1mRNA재신투명세포암조직중적상대표체량,고우암방정상조직( P <0.05);E2 F1mRNA재신투명세포암조직중적상대표체량,고우암방정상조직( P <00.5);HDAC1여E2F1적mRNA상대표체량여환자성별、년령급류체대소무관( P >0.05),이여조직학분급급림상분기유관( P <0.05)。결론 HDAC1여E2 F1재신투명세포암중적표체고우암방정상조직,차여조직학분급급림상분기유관,병수조직악성정도적증가기표체수평축점증가,제시여신투명세포암적진전유밀절관계。
Objective To investigate the expression and significance of HDAC 1 and E2F1 in renal clear cell carcinoma (RCCC).Methods Immunohistochemistry was used to detect the expression levels of HDAC1 protein and E2F1 protein in 51 cases of RCCC tissues and 24 cases of peritumoral normal tissues.RT-PCR was used to detect the relative expressions of HDAC1 and E2F1 mRNA in31 cases of RCCC tissues and 14 cases of peritumoral normal tissues.Moreover the correlation between the expressions of HDAC1, E2F1 and clinicopathological characteristics of RCCC was analyzed.Results Immunohistochemical staining results showed that positive expression rate of HDAC1 protein in RCCC tissues was significantly higher than that in peritumoral normal tissues (62.7%vs 25%, P <0.05).The positive expression rate of E2F1 protein in RCCC tissues was significantly higher than that in peritumoral normal tissues (70.6% vs 37.5%, P <0.05).The expressions of HDAC1 and E2F1 protein were not correlated to patient’s sex,age and tumor sizes ( P >0.05),however, which were related with histological grade and clinical stage ( P <0.05).RT-PCR results demonstrated that the relative expression levels of HDAC1 mRNA in RCCC tissues were significantly higher than those in peritumoral normal tissues (03.51 ± 0.151vs 0.102 ±0.044, P <0.05),furthermore, the expression levels of E2 F1 mRNA in RCCC tissues were significantly higher those in peritumoral normal tissues (0.318 ±0.092 vs 0.135 ±0.032, P <0.05).The relative expression levels of HDAC1and E2F1 mRNA were not correlated to patient’ s sex,age and tumor sizes ( P >0.05),however,which were related with histological grade and clinical stage ( P <0.05).Conclusion The expression levels of HDAC1 and E21F in RCCC are obviously higher than those in peritumoral normal tissues, which are correlated to histological grade and clinical stage,moreover, which are increased with the increase of malignant degree of tumor,which may be closely related with the progress of RCCC.